World Market for Prescription Arthritis Treatments
Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians.
While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:
For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.
There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis. Additionally, combination therapies continue to grow in preference and offer exciting results in disease management.
This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides market sizes and forecasts for the following categories of treatments:
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Biologic Response Modifiers (BRMs) and Immunosuppressants
For each category, the report breaks down the regional market (US, Europe, Japan, Rest of World), lists major products, and provides market share among major competitors.
There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include:
- US Economic Impact of Arthritis
- World Economic Impact of Arthritis
- Obesity and Arthritis
- Trends in Insurance and Reimbursement
- Threat to Anti-TNF Dominance
- ADAM-12 Gene Discovery
- New Pricing Structure in Germany
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the worldwide arthritis treatment market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 20 industry executives and product managers to validate and obtain expert opinion on current and future trends in the worldwide prescription arthritis treatment market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Product Market Summary
Issues and Trends Affecting Market
Competitor Analysis
CHAPTER TWO: INTRODUCTION
Overview
Local Joint Disorder Function
Etiology and Pathogenesis
Clinical Manifestations
Osteoarthritis
Etiology and Pathogenesis
Clinical Manifestations
Treatment
Infectious Arthritis
Etiology and Pathogenesis
Clinical Manifestations
Systemic Disorders of Joint Function
Rheumatoid Arthritis
Etiology and Pathogenesis
Clinical Manifestations
Ankylosing Spondylitis
Clinical Manifestations
Psoriatic Arthritis
Clinical Manifestations
Enteropathic Arthritis
Clinical Manifestations
Adult Onset Still Disease
Clinical Manifestations
Juvenile Rheumatoid Arthritis
Clinical Manifestations
Still Disease
Polyarticular Onset
World Demographics
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
Product Description
Market Forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
Product Descriiption
Sulfasalazine (Azulfidine-Pfizer)
Gold Compounds
Penicillamine (Cuprimine-Merck)
Chloroquine (Aralen-Sanofi-Aventis)
Methotrexate (Trexall-Duramed; Rheumatrex-DAVA Pharmaceuticals)
Leflunomide (Arava-Sanofi-Aventis)
Market Forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
Description
Tumor Necrosis Factor
Glucocorticoids
Azathioprine (Azasan-Salix)
Adalimumab (Humira-Abbott)
Anakinra (Kineret-Amgen)
Basiliximab (Simulect-Novartis)
Daclizumab (Zenapax-Roche)
Etanercept (Enbrel-Amgen)
Infliximab (Remicade-Janssen Biotech)
Rituximab (Rituxan-Biogen Idec)
Abatacept (Orencia-Bristol-Myers Squibb)
Market forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
Market Overview
Product Market Summary
Product Market Analysis by Geographical Region
6 Worldwide Arthritis Treatment Products Competitive Analysis
CHAPTER SEVEN: ARTHRITIS RESEARCH AND DEVELOPMENT TREATMENTS
Overview
Duexis
Gel-One
ACZ
Apremilast
Fostamatinib
Lodotra
Stelara
Tofacitinib
CHAPTER EIGHT: ARTHRITIS TREATMENTS ISSUES AND TRENDS
Overview
US Economic Impact of Arthritis
World Economic Impact of Arthritis
Obesity and Arthritis
Trends in Insurance and Reimbursement
Threat to Anti-TNF Dominance
ADAM- Gene Discovery
New Pricing Structure in Germany
CHAPTER SEVEN: CONCLUSIONS
Conclusion One
Conclusion Two
Conclusion Three
Conclusion Four
Conclusion Five
CHAPTER EIGHT: COMPANY PROFILES
Introduction
Abbott Laboratories
Amgen, Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Galapagos NV
Genentech, Inc.
Horizon Pharma
Janssen Biotech, Inc
Novartis International AG
Pfizer, Inc.
Roche
Regeneron
UCB
LIST OF COMPANIES
Introduction
Scope and Methodology
Product Market Summary
Issues and Trends Affecting Market
Competitor Analysis
CHAPTER TWO: INTRODUCTION
Overview
Local Joint Disorder Function
Etiology and Pathogenesis
Clinical Manifestations
Osteoarthritis
Etiology and Pathogenesis
Clinical Manifestations
Treatment
Infectious Arthritis
Etiology and Pathogenesis
Clinical Manifestations
Systemic Disorders of Joint Function
Rheumatoid Arthritis
Etiology and Pathogenesis
Clinical Manifestations
Ankylosing Spondylitis
Clinical Manifestations
Psoriatic Arthritis
Clinical Manifestations
Enteropathic Arthritis
Clinical Manifestations
Adult Onset Still Disease
Clinical Manifestations
Juvenile Rheumatoid Arthritis
Clinical Manifestations
Still Disease
Polyarticular Onset
World Demographics
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
Product Description
Market Forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
Product Descriiption
Sulfasalazine (Azulfidine-Pfizer)
Gold Compounds
Penicillamine (Cuprimine-Merck)
Chloroquine (Aralen-Sanofi-Aventis)
Methotrexate (Trexall-Duramed; Rheumatrex-DAVA Pharmaceuticals)
Leflunomide (Arava-Sanofi-Aventis)
Market Forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
Description
Tumor Necrosis Factor
Glucocorticoids
Azathioprine (Azasan-Salix)
Adalimumab (Humira-Abbott)
Anakinra (Kineret-Amgen)
Basiliximab (Simulect-Novartis)
Daclizumab (Zenapax-Roche)
Etanercept (Enbrel-Amgen)
Infliximab (Remicade-Janssen Biotech)
Rituximab (Rituxan-Biogen Idec)
Abatacept (Orencia-Bristol-Myers Squibb)
Market forecast and Growth
Markets by Geographical Region
United States
Europe
Japan
Rest of World
Competitive Landscape
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
Market Overview
Product Market Summary
Product Market Analysis by Geographical Region
6 Worldwide Arthritis Treatment Products Competitive Analysis
CHAPTER SEVEN: ARTHRITIS RESEARCH AND DEVELOPMENT TREATMENTS
Overview
Duexis
Gel-One
ACZ
Apremilast
Fostamatinib
Lodotra
Stelara
Tofacitinib
CHAPTER EIGHT: ARTHRITIS TREATMENTS ISSUES AND TRENDS
Overview
US Economic Impact of Arthritis
World Economic Impact of Arthritis
Obesity and Arthritis
Trends in Insurance and Reimbursement
Threat to Anti-TNF Dominance
ADAM- Gene Discovery
New Pricing Structure in Germany
CHAPTER SEVEN: CONCLUSIONS
Conclusion One
Conclusion Two
Conclusion Three
Conclusion Four
Conclusion Five
CHAPTER EIGHT: COMPANY PROFILES
Introduction
Abbott Laboratories
Amgen, Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb
Galapagos NV
Genentech, Inc.
Horizon Pharma
Janssen Biotech, Inc
Novartis International AG
Pfizer, Inc.
Roche
Regeneron
UCB
LIST OF COMPANIES
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Summary Table: Total World Arthritis Treatment Revenue and Growth Rate by Drug Type 2011 ($millions)
Summary Figure:The World Prescription Arthritis Treatments Market Share Summary 2011
CHAPTER TWO: INTRODUCTION
Table 2-1: Total Global Population by Selected Geographical Region, 2000 - 2050
Table 2-2 World Prevalence of Rheumatoid Arthritis by Region
Figure 2-1:: World Prevalence of Rheumatoid Arthritis, Percent by Region
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
Table 3-1: Select Marketed Non-steroidal Anti-inflammatory Drugs
Table 3-2 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 3-1 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Table 3-3: The Worldwide Market for NSAIDs by Geographical Region (US, Europe, ROW) 2009-2016
Figure 3-2: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2011
Figure 3-3: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2016
Table 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
Figure 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
Table 4-2: Market Size and Growth for DMARDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 4-1: Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
Table 5-1: Selected Prescription Immunosuppressant and Other Biologic Drugs
Table 5-2 Market Size and Growth for BMRs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 5-1 Market Size and Growth for BRMs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
Table 5-3: The Worldwide Market for BRMs by Geographical Region (US, Europe, Japan, ROW) 2009-2016
Figure 5-2: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2011
Figure 5-3: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2016
Table 5-4: The World Biologic Response Modifiers Arthritis Treatment nd Market Share by Supplier 2011
Figure 5-4: The Worldwide BRMs and Immunosuppressives Product Market Share by Supplier 2011
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
Table 6-1: Total World Prescription Arthritis Treatment Revenue and Growth Rate by Drug Type 2011
Figure 6-1: The World Prescription Arthritis Treatments Market Share Summary 2011
Table 6-3: The World Market for Prescription Arthritis Treatments, by Geographic Region, 2011
Figure 6-2: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2011
CHAPTER ONE: EXECUTIVE SUMMARY
Summary Table: Total World Arthritis Treatment Revenue and Growth Rate by Drug Type 2011 ($millions)
Summary Figure:The World Prescription Arthritis Treatments Market Share Summary 2011
CHAPTER TWO: INTRODUCTION
Table 2-1: Total Global Population by Selected Geographical Region, 2000 - 2050
Table 2-2 World Prevalence of Rheumatoid Arthritis by Region
Figure 2-1:: World Prevalence of Rheumatoid Arthritis, Percent by Region
CHAPTER THREE: WORLDWIDE NON-STEROIDAL ANTI-INFLAMMATORY DRUG MARKET
Table 3-1: Select Marketed Non-steroidal Anti-inflammatory Drugs
Table 3-2 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 3-1 Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Table 3-3: The Worldwide Market for NSAIDs by Geographical Region (US, Europe, ROW) 2009-2016
Figure 3-2: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2011
Figure 3-3: The Worldwide Market for NSAIDs Products by Region (US, Europe, Japan, ROW), 2016
Table 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
Figure 3-4: The Worldwide NSAIDs Product Market Share by Supplier 2011
CHAPTER FOUR: WORLDWIDE DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TREATMENT MARKETS
Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
Table 4-2: Market Size and Growth for DMARDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 4-1: Market Size and Growth for NSAIDs in the Global Arthritis Treatment Market 2009-2016 ($millions)
CHAPTER FIVE: WORLDWIDE BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOSUPPRESSIVE DRUG MARKETS
Table 5-1: Selected Prescription Immunosuppressant and Other Biologic Drugs
Table 5-2 Market Size and Growth for BMRs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
Figure 5-1 Market Size and Growth for BRMs and Immunosuppressants in the Global Arthritis Treatment Market 2009-2016 ($millions)
Table 5-3: The Worldwide Market for BRMs by Geographical Region (US, Europe, Japan, ROW) 2009-2016
Figure 5-2: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2011
Figure 5-3: The Worldwide Market for BRM Products by Region (US, Europe, Japan, ROW), 2016
Table 5-4: The World Biologic Response Modifiers Arthritis Treatment nd Market Share by Supplier 2011
Figure 5-4: The Worldwide BRMs and Immunosuppressives Product Market Share by Supplier 2011
CHAPTER SIX: WORLDWIDE ARTHRITIS TREATMENT MARKET SUMMARY AND COMPETITIVE ANALYSIS
Table 6-1: Total World Prescription Arthritis Treatment Revenue and Growth Rate by Drug Type 2011
Figure 6-1: The World Prescription Arthritis Treatments Market Share Summary 2011
Table 6-3: The World Market for Prescription Arthritis Treatments, by Geographic Region, 2011
Figure 6-2: The World Market for Prescription Rheumatoid Arthritis, by Geographic Region, 2011
